February 28, 2025
South Korea is a rapidly growing hub for the pharmaceutical and biotechnology industry, offering a well-structured and globally aligned regulatory framework. To commercialize pharmaceutical products in this market, companies must obtain approval through the Marketing Authorization Application (MAA) process governed by the Ministry of Food and Drug Safety (MFDS).
With increasing alignment to ICH guidelines and global regulatory standards, the MFDS approval process demands robust scientific data, strategic planning, and regulatory expertise.
Marketing Authorization Applications (MAAs) in South Korea are regulated by the Ministry of Food and Drug Safety (MFDS) and require submission in CTD format, including quality, nonclinical, and clinical data. The process involves administrative and scientific review, GMP inspection, and post-marketing compliance to ensure drug safety, efficacy, and quality before approval.
This comprehensive 2026 guide by Maven Regulatory Solutions provides an in-depth overview of the MAA process in South Korea, including regulatory pathways, CTD requirements, approval timelines, and compliance strategies.
Regulatory Authority: Role Of MFDS
The MFDS is the primary regulatory authority responsible for:
- Evaluating drug safety, efficacy, and quality
- Reviewing clinical and nonclinical data
- Conducting GMP inspections
- Monitoring post-marketing safety
Global Alignment
MFDS aligns with:
- ICH (International Council for Harmonization)
- WHO (World Health Organization)
- Global pharmacovigilance standards
Key Regulations Governing MAA In South Korea
| Regulation | Scope |
| Pharmaceutical Affairs Act | Governs drug manufacturing, import, and distribution |
| Regulations on Safety of Pharmaceuticals | Pharmacovigilance and risk management |
| Good Manufacturing Practice (GMP) | Quality systems and manufacturing compliance |
| Drug Approval Review Guidelines | Data requirements for approval |
Types Of Marketing Authorization Applications (MAAs)
| Application Type | Description |
| New Drug Application (NDA) | Innovative drugs with new active ingredients |
| Generic Drug Application (GDA) | Bioequivalent versions of approved drugs |
| Biologics License Application (BLA) | Biologics and biosimilars |
| Orphaned Drug Application | Rare disease treatments with incentives |
| OTC Drug Application | Non-prescription products |
Step-by-Step MAA Process in South Korea
Step 1: Pre-Submission Consultation (Recommended)
- Engage with MFDS for regulatory guidance
- Clarify data expectations and submission strategy
- Identify potential gaps early
Step 2: CTD Dossier Preparation and Submission
All MAAs must follow the Common Technical Document (CTD) format:
| Module | Content |
| Module 1 | Administrative and regional information |
| Module 2 | Summaries of quality, nonclinical, and clinical data |
| Module 3 | Quality (CMC and GMP compliance) |
| Module 4 | Nonclinical studies (toxicology, pharmacology) |
| Module 5 | Clinical data (safety and efficacy studies) |
Step 3: MFDS Review and Evaluation
The MFDS review process includes:
- Administrative Review: Completeness check
- Scientific Review: Evaluation of safety, efficacy, and quality
- GMP Inspection: Facility compliance verification
- Expert Advisory Review: For complex or high-risk products
Step 4: Approval Or Request for Information (RFI)
- Approval granted if all requirements are met
- MFDS may issue RFI (Request for Information) for clarification or additional data
- Timely response is critical to avoid delays
Step 5: Post-Approval Compliance
After approval, companies must maintain compliance through:
- Pharmacovigilance (PSURs, adverse event reporting)
- Post-marketing surveillance (PMS) studies
- License renewal (typically every 5 years)
Estimated Approval Timelines
| Application Type | Timeline |
| NDA | 12–24 months |
| Generic (GDA) | 6–12 months |
| Biologics (BLA) | 12–18 months |
| Orphan Drugs | Accelerated timelines |
Expedited Regulatory Pathways in South Korea
MFDS offers accelerated pathways for innovative therapies:
- Priority Review: For unmet medical needs
- Conditional Approval: Based on limited clinical data
- Fast-Track Approval: For significant therapeutic benefits
These pathways significantly reduce time-to-market for critical therapies.
Common Challenges in MAA Submission
| Challenge | Impact | Solution |
| Regulatory differences | Submission delays | Local regulatory expertise |
| Language requirements | Compliance issues | Korean translation support |
| Complex clinical data | Review delays | Early alignment with MFDS |
| GMP inspection readiness | Approval risk | Pre-audit preparation |
Latest Trends in MFDS Drug Approval
- Increased adoption of eCTD submissions
- Enhanced focus on real-world evidence (RWE)
- Expansion of biologics and biosimilars approvals
- Integration of AI in regulatory review processes
- Strengthened pharmacovigilance requirements
Why Choose Maven Regulatory Solutions?
Maven Regulatory Solutions offers:
- End-to-end MAA submission support
- CTD and eCTD dossier preparation
- MFDS regulatory strategy and consulting
- GMP compliance and audit readiness
- Pharmacovigilance and lifecycle management
We ensure efficient approvals, reduced regulatory risk, and faster market access in South Korea.
Conclusion
Successfully navigating the MAA process in South Korea requires a comprehensive understanding of MFDS regulations, CTD requirements, and post-marketing obligations. With evolving regulatory expectations in 2026, companies must adopt a strategic, data-driven, and compliant approach to achieve timely approvals.
By partnering with Maven Regulatory Solutions, pharmaceutical companies can streamline their regulatory journey and unlock opportunities in one of Asia’s most dynamic healthcare markets.
FAQs
1. What is an MAA in South Korea?
An MAA is the application submitted to MFDS to obtain approval for marketing pharmaceutical products.
2. Is CTD format mandatory for MFDS submissions?
Yes, all MAAs must follow the CTD format aligned with ICH guidelines.
3. How long does MFDS approval take?
Approval timelines range from 6 to 24 months depending on the application type.
4. What is an RFI in MFDS review?
RFI (Request for Information) is issued when additional data or clarification is required.
5. Are expedited approval pathways available in Korea?
Yes, MFDS offers priority, conditional, and fast-track approvals for eligible products.
Post a comment